NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,423.70 -14.80 (-0.61%) DOW
39,835.58 +28.81 (+0.07%) Bitcoin GBP
54,889.32 +872.75 (+1.62%)
GSK Aug 2024 46.000 call
| Previous close | 1.2500 |
| Open | 1.2500 |
| Bid | 1.1000 |
| Ask | 1.1500 |
| Strike | 46.00 |
| Expiry date | 2024-08-16 |
| Day's range | 1.2500 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 380 |
BenzingaGSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Tuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterized by blood eosinophil count. Earlier this year, GSK acquired Aiolos Bio Inc., a privately held asthma drug maker, for $1 billion. Both SWIFT-1 and SWIFT-2 met their primary endpoints of a reduction in the annualized rate of clinically sign
BloombergGSK’s New Vaccine Kept the Boss in Her Job — and an Activist at Bay
(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergOne Dead After Singapore Air Flight Hit By Severe TurbulenceASML, TSMC Can Disable Chip Machines If China Invades TaiwanHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’Tesla Shareholder Group Slams Elon Musk’s
ReutersGSK whistleblower claims drugmaker cheated US government over Zantac cancer risk
(Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by concealing cancer risks in Zantac, once a blockbuster heartburn drug. In a whistleblower complaint filed on Monday, Valisure said GSK violated the federal False Claims Act by hiding the risks for nearly four decades while Medicare, Medicaid and other health programs covered billions of dollars of prescriptions. The New Haven-based lab said its testing in 2019 revealed that Zantac, also known as ranitidine, could form a cancer-causing carcinogen known as NMDA and was therefore "unfit for human consumption."
